Check out what we have in store for you in the October 2015 Newsletter -
HCV Drugs by Alan Franciscus, Editor-in-Chief
Read about Achillion’s latest clinical trial results from their PROXY study, information about insurance denials, how far we have come in treating the most difficult to treat patients, but how far we still have to go to cure everyone with hepatitis C, drug-drug interactions and re-treatment issues.
HealthWise by Lucinda K. Porter, RN
In this month’s column, Lucinda answers some important post-treatment questions from people living with hepatitis C.
What The Heck Are RAVs? by Alan Franciscus, Editor-in-Chief
If you have been treated before with a direct-acting antiviral medication, but not cured, this brief overview is an important topic to understand.
SnapShots by Alan Franciscus, Editor-in-Chief
Three studies that look at treating people with advanced liver disease and re-treatment of people who had been previously treated with direct-acting antiviral medications but did not achieve a cure.
What's New? by Alan Franciscus, Editor-in-Chief
We have merged our HBV Website to our HCV Website – find out more…. Don’t forget to check out our newly re-designed Facebook and Twitter accounts! Just go to Facebook and Twitter and type in 'HCV Advocate'. Follow us and learn all the latest information about hepatitis C and about what we are doing.
Labels: HCV Advocate Newsletter October 2015